The continuing education portion of this activity is being supported by ineligible companies in the form of independent medical education grants.  All companies and relationships will be disclosed and mitigated prior to the start of the activity.

PHYSICIANS

In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Objectives (ACCME, ANCC, ACPE)

Upon completion of this activity, the participant should be able to:

1. Analyze the new data and research available from respected institutions.
2. Assess new therapies available to treat patients and know how to incorporate these therapies into practice.
3. Evaluate new drug therapies including the mechanism of action (MOA).
4. Identify barriers that may prevent healthcare professionals from implementing new therapies into their practice and understanding steps they can take to address these barriers.
5. Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies to increase equitable optimal management of treatment plans and care to patients to minimize risk and adverse effects (e.g., toxicity) and improve patient outcomes, survival, and quality of life.
6. Evaluate the best treatment options for AML patients where transplantation is not an option.
7. Identify the emerging and targeted therapies for the treatment of Relapsed and Refractory AML and describe how to put these treatment options into practice.
8. Identify the emerging treatment options for Myelodysplastic Syndromes and describe how to put these treatment options into practice.
9. Discuss treatment options for managing patients with Chronic Myeloid Leukemia in the current landscape.
10. Identify the new treatment options for Multiple Myeloma and describe how to put these treatment options into practice.
11. Describe management of adverse reactions to Multiple Myeloma therapy.
12. Review the emerging treatment options for Relapsed / Refractory Multiple Myeloma and describe how to put these treatment options into practice.
13. Evaluate the most current and treatment options for Waldenstrom’s Macroglobulinemia.
14. Assess and adjust diagnostic and treatment strategies for patients with Amyloidosis to include latest options.
15. Describe the current landscape surrounding treatment recommendations for patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia.
16. Identify the most effective therapies needed to manage bleeding and clotting disorders such as Sickle Cell Disease.
17. Evaluate the diagnosis for Myeloproliferative Neoplasms including how best to treat this disease. 
18. Improve the management of patients with Myelofibrosis, Philadelphia Chromosome Negative Myeloproliferative Neoplasms and Systemic Mastocytocsis in their practice.
19. Identify the emerging treatment options for Acute Lymphoblastic Leukemia and describe how to put these treatment options into practice.
20. Explain how to effectively implement new Immune Effector Cell therapies for Lymphoid Malignancies in a community practice. 
21. Evaluate the diagnosis for cellular blood disorders including how best to treat Initial and Relapsed Chronic Lymphocytic Leukemia.
22. Explain when it is important to “watch and wait” vs. treating patients with Indolent Lymphoma and Mantle Cell Lymphoma.
23. Adjust diagnostic and treatment strategies for patients with Hodgkin’s Lymphoma to include latest options.
24. Identify the emerging treatment options for Aggressive B and T Cell Lymphomas and describe how to put these treatment options into practice.
25. Explain how to effectively implement new Immune Effector Cell therapies for Multiple Myeloma in a community practice. 
26. Discuss when it is important to refer vs. treat patients who have had Hematopoietic Transplantation and are on Cellular therapies.

Physician Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Purdue University College of Pharmacy designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Symposium – 7:30 am – 7:15 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ (Town Hall Interactive Meeting – 7:30 – 8:30 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosure / Conflict of Interest Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Disclosures will be provided prior to the start of the activity. All relevant conflicts of interest will have been mitigated prior to the start of the activity.

None of the planners, reviewers, Indy Hematology Education, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

NURSES

In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.

Nurses Accreditation Statement

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This program is approved for 9.5 contact hours (Symposium: 7:30 am – 7:15 pm). This program is approved for 1.0 contact hour (Town Hall Interactive Meeting: 7:30 pm – 8:30 pm).

PHARMACISTS

In order to receive CE, you must attend the entire Symposium from 7:30 am – 7:15 pm. Successful completion of this CME activity requires participants to complete a post-evaluation.

Pharmacists Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution.

Symposium: 7:30 am – 7:15 pm.

Universal Activity Number (UAN): 0018-9999-24-001-L01-P

This program is approved for 9.5 contact hours (0.95 CEU’s).

Town Hall Interactive Meeting: 7:30 pm – 8:30 pm.

Universal Activity Number (UAN): 0018-9999-24-001-L01-P

This program is approved for 1.0 contact hours (0.10 CEU’s).